C4 Therapeutics, Inc. (CCCC) Tops Q2 EPS by 3c

C4 Therapeutics, Inc. (NASDAQ: CCCC) reported Q2 EPS of ($0.37), $0.03 better than the analyst estimate of ($0.40).

For earnings history and earnings-related data on C4 Therapeutics, Inc. (CCCC) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• Sypris Solutions (SYPR) Reports Q2 Loss of $0.14
• Freedom Broker Downgrades Flexsteel (FLXS) to Hold